| 國立成功大學 |
2023 |
Association of prognostic nutritional index with risk of contrast induced nephropathy: A meta-analysis
|
Chang, W.-T.;Sun, C.-K.;Wu, J.-Y.;Huang, P.-Y.;Liu, T.-H.;Chang, Y.-J.;Lin, Y.-T.;Kang, F.-C.;Hung, K.-C. |
| 臺大學術典藏 |
2022-09-07T07:41:22Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; HAN-MO CHIU; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:50:06Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; YI-CHIA LEE; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:50:01Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-09-07T06:49:54Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; YI-CHIA LEE; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:53Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:45Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; YI-CHIA LEE; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:44Z |
The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal
|
Wu J.-Y.; YI-CHIA LEE; Graham D.Y. |
| 臺大學術典藏 |
2022-09-07T06:49:38Z |
Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus
|
Liou J.-M.; Malfertheiner P.; YI-CHIA LEE; Sheu B.-S.; Sugano K.; Cheng H.-C.; Yeoh K.-G.; Hsu P.-I.; Goh K.-L.; Mahachai V.; Gotoda T.; Chang W.-L.; Chen M.-J.; Chiang T.-H.; Chen C.-C.; Wu C.-Y.; Leow A.H.-R.; Wu J.-Y.; Wu D.-C.; Hong T.-C.; Lu H.; Yamaoka Y.; Megraud F.; Chan F.K.L.; Sung J.J.Y.; Lin J.-T.; Graham D.Y.; Wu M.-S.; El-Omar E.M. |
| 臺大學術典藏 |
2022-09-07T06:49:31Z |
Screening and eradication of Helicobacter pylori to prevent gastric cancer in indigenous Taiwanese communities: a population-based study and development of an index-case method
|
Lei W.-Y.; Lee J.-Y.; Chen C.-L.; Bair M.-J.; Wu J.-Y.; Wu D.-C.; Tien H.-W.; Lin L.-J.; Hsuttt T.-H.; YI-CHIA LEE |
| 臺大學術典藏 |
2022-09-06T07:43:07Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; MING-SHIANG WU; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2022-09-02T02:56:33Z |
Genome-wide analysis of copy number variations identifies PARK2 as a candidate gene for autism spectrum disorder
|
Liao H.-M.; Chou M.C.; Chou W.-J.; Tsai W.-C.; Chiu Y.-N.; Wu Y.-Y.; Lo C.-Z.; Wu J.-Y.; Chen Y.-T.; SUSAN SHUR-FEN GAU; Chien Y.-L.; Chen H.-I.; Li L.-H.; Yin C.-L. |
| 臺大學術典藏 |
2022-09-02T02:56:12Z |
Allele-specific expression in a family quartet with autism reveals mono-to-biallelic switch and novel transcriptional processes of autism susceptibility genes
|
SUSAN SHUR-FEN GAU; Huang H.-S.; Huang P.-H.; Ho H.-N.; Akbarian S.; Coon H.; Wu J.-Y.; Lin C.-Y.; Lin C.-Y.; Chang K.-W. |
| 臺大學術典藏 |
2022-08-09T03:51:04Z |
High-temperature Raman study in CVD diamond
|
Chen K.-H.; Lai Y.-L.; Chen L.-C.; Wu J.-Y.; Kao F.-J.; Chen K.-H.; Lai Y.-L.; Chen L.-C.; Wu J.-Y.; Kao F.-J.; LI-CHYONG CHEN |
| 臺大學術典藏 |
2022-08-09T03:51:03Z |
On the optimized nucleation of near-single-crystal CVD diamond film
|
Chen L.C.; Juan C.C.; Wu J.Y.; Chen K.H.; Teng J.W.; Chen L.C.; Juan C.C.; Wu J.Y.; Chen K.H.; Teng J.W.; LI-CHYONG CHEN |
| 臺大學術典藏 |
2022-06-27T07:07:54Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
|
Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; CHONG-JEN YU; Tsai M.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:47Z |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
|
Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; CHONG-JEN YU; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:47Z |
The role of chest radiography in the suspicion for and diagnosis of pulmonary tuberculosis in intensive care units
|
Wu J-Y.; Ku S-C.; Shu C-C.; Fan J-Y.; Chen H-Y.; Chen Y-C.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T07:07:44Z |
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Shih J.-Y.; Yang C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:43Z |
Kommerell diverticulum, right-sided aorta, and left aberrant subclavian artery in a patient with dysphagia
|
Wu J.-Y.; Chen H.-Y.; Shu C.-C.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T07:07:42Z |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer
|
Wu J.-Y.; Yang C.-H.; Hsu Y.-C.; CHONG-JEN YU; Chang S.-H.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:36Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; CHONG-JEN YU; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:35Z |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Chang Y.-C.; Yang C.-H.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:21Z |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
|
Wu J.-Y.; Wu S.-G.; Yang C.-H.; Gow C.-H.; Chang Y.-L.; CHONG-JEN YU; Shin J.-Y.; Yang P.-C. |
